This is a non-binding aspirational announcement with no definitive agreements. The $100M target is an order of magnitude above the current market cap, but the stock's history shows severe negative drift following prior neutral-score filings. Treat as noise until a definitive acquisition agreement is filed or priced equity offering is announced. Monitor for 8-K filing of any signed definitive agreement.
Price Chart
Executive Summary
Tevogen Bio announced it is evaluating strategic acquisitions that could generate approximately $100 million in combined annual revenue, including a previously disclosed CRO deal. However, these remain highly preliminary — subject to due diligence, definitive agreements, and approvals — and no transaction is assured. The company has no current revenue and a $30M market cap, making the aspirational $100M revenue target highly speculative.
Key Financial Metrics
Key Facts
- Tevogen is evaluating a CRO acquisition and other strategic opportunities to build a revenue-generating healthcare enterprise.
- The company believes acquisitions could realize approximately $100 million in combined annual revenue if consummated.
- Proposed transactions remain subject to due diligence, definitive documentation, approvals, and customary closing conditions.
- No assurance any transaction will be consummated; no definitive agreements have been signed.
- Tevogen has a market cap of ~$30M and is pre-revenue in its core biotech operations.
Financial Impact
Potential ~$100M annual revenue if acquisitions close, but currently pre-revenue with $30M market cap. No transaction probability or terms disclosed.
Risk Factors
- No definitive agreements in place — transactions may never close or may close on materially worse terms.
- Company has no current revenue and limited cash; any acquisition would require dilutive financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303124 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $6.72 | awaiting T+60 | — | $6.25 (−6.99%) |
Sep 16, 2026 5w ago | SC 13D/A | $7.71 | awaiting T+60 | — | $6.25 (−18.94%) |
Sep 16, 2026 5w ago | SC 13D/A | $7.71 | awaiting T+60 | — | $6.25 (−18.94%) |
Sep 16, 2026 5w ago | 8-K | $7.71 | awaiting T+60 | — | $6.25 (−18.94%) |
Jun 26, 2026 17w ago | EFFECT | $7.00 $7.43 | ▼ −6.14% | ▼ −1.66% | $6.25 (+10.71%) |
Jun 12, 2026 19w ago | S-3 | $10.02 $7.34 | ▲ +26.75% | ▲ +27.75% | $6.25 (+37.62%) |
Jun 9, 2026 19w ago | Press Release | $10.75 $7.17 | ▼ −33.30% | ▼ −37.12% | $6.25 (−41.86%) |
May 28, 2026 21w ago | Press Release | $8.04 $6.75 | ▼ −16.04% | ▼ −17.78% | $6.25 (−22.26%) |
May 21, 2026 22w ago | Press Release | $11.57 $6.58 | ▼ −43.10% | ▼ −47.40% | $6.25 (−45.96%) |
Mar 25, 2026 30w ago | Press Release | $5.18 $9.79 | ▲ +88.90% | ▲ +75.44% | $6.25 (+20.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers